EP4126945A4 - Methods and treatment involving excess free light - Google Patents

Methods and treatment involving excess free light

Info

Publication number
EP4126945A4
EP4126945A4 EP21779221.7A EP21779221A EP4126945A4 EP 4126945 A4 EP4126945 A4 EP 4126945A4 EP 21779221 A EP21779221 A EP 21779221A EP 4126945 A4 EP4126945 A4 EP 4126945A4
Authority
EP
European Patent Office
Prior art keywords
methods
free light
treatment involving
excess free
involving excess
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21779221.7A
Other languages
German (de)
French (fr)
Other versions
EP4126945A2 (en
Inventor
Garry A Neil
Inbal Zafir-Lavie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avalo Therapeutics Inc
Original Assignee
Avalo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avalo Therapeutics Inc filed Critical Avalo Therapeutics Inc
Publication of EP4126945A2 publication Critical patent/EP4126945A2/en
Publication of EP4126945A4 publication Critical patent/EP4126945A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
EP21779221.7A 2020-04-01 2021-03-31 Methods and treatment involving excess free light Pending EP4126945A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063003826P 2020-04-01 2020-04-01
US202063027127P 2020-05-19 2020-05-19
US202163133636P 2021-01-04 2021-01-04
PCT/US2021/025068 WO2021202649A2 (en) 2020-04-01 2021-03-31 Methods and treatment involving excess free light

Publications (2)

Publication Number Publication Date
EP4126945A2 EP4126945A2 (en) 2023-02-08
EP4126945A4 true EP4126945A4 (en) 2024-02-28

Family

ID=77929895

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21779221.7A Pending EP4126945A4 (en) 2020-04-01 2021-03-31 Methods and treatment involving excess free light

Country Status (10)

Country Link
US (2) US11708406B2 (en)
EP (1) EP4126945A4 (en)
JP (1) JP2023520216A (en)
KR (1) KR20220161387A (en)
AU (1) AU2021248833A1 (en)
BR (1) BR112022019112A2 (en)
CA (1) CA3173873A1 (en)
MX (1) MX2022011811A (en)
TW (1) TW202204405A (en)
WO (1) WO2021202649A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008027338A2 (en) * 2006-08-28 2008-03-06 Kyowa Hakko Kirin Co., Limited Antagonistic human light-specific human monoclonal antibodies
US20190315876A1 (en) * 2018-01-24 2019-10-17 Capella Bioscience Ltd. Antigen Binding Molecules That Bind LIGHT

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140467A (en) 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6998108B1 (en) 1997-07-07 2006-02-14 La Jolla Institute For Allergy And Immunology Antibodies to p30 polypeptides and methods making and using same
US7118742B2 (en) 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
DE60129010T2 (en) 2000-04-12 2008-02-28 La Jolla Institute For Allergy And Immunology, San Diego LIGAND OF THE CELL INTRUSION-PROCESSING PROTEIN OF HERPES SIMPLEX AND METHODS FOR ITS USE
US8349320B2 (en) 2004-12-09 2013-01-08 La Jolla Institute For Allergy And Immunology Compositions and methods for modulating responses mediated or associated with BTLA activity
US8153123B2 (en) 2004-12-09 2012-04-10 La Jolla Institute For Allergy And Immunology Method for restoring dendritic cell populations
EP2160200B1 (en) 2007-05-14 2013-07-10 The University of Chicago Antibody-LIGHT fusion products as cancer therapeutics
EP3750554A3 (en) 2007-09-18 2021-07-28 La Jolla Institute for Allergy and Immunology Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment
US9700606B2 (en) 2008-07-08 2017-07-11 La Jolla Institute For Allergy And Immunology HVEM/BTLA, HVEM/CD 160 and HVEM/gD cis complexes and methods of use
RU2542394C2 (en) 2009-03-24 2015-02-20 ТЕВА БИОФАРМАСЬЮТИКАЛЗ ЮЭсЭй, ИНК. Humanised anti-light antibodies and using them
WO2013081143A1 (en) 2011-11-30 2013-06-06 中外製薬株式会社 Drug containing carrier into cell for forming immune complex
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US20130315913A1 (en) 2012-03-26 2013-11-28 Sanofi Anti-light antibody therapy for inflammatory bowel disease
ES2648176T3 (en) 2012-07-12 2017-12-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting survival time and response to treatment of a patient suffering from solid cancer with a hallmark of at least 7 genes
US10259880B2 (en) 2014-01-14 2019-04-16 Kymab Limited Anti-LIGHT antibodies
US20150307620A1 (en) 2014-04-16 2015-10-29 University Of Connecticut Linked immunotherapeutic agonists that costimulate multiple pathways
AU2016313504A1 (en) * 2015-08-21 2018-03-08 The Children's Hospital Of Philadelphia Compositions and methods for use in combination for the treatment and diagnosis of autoimmune diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008027338A2 (en) * 2006-08-28 2008-03-06 Kyowa Hakko Kirin Co., Limited Antagonistic human light-specific human monoclonal antibodies
US20190315876A1 (en) * 2018-01-24 2019-10-17 Capella Bioscience Ltd. Antigen Binding Molecules That Bind LIGHT

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CONVERTINO IRMA ET AL: "Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients", CRITICAL CARE, vol. 24, no. 1, 11 June 2020 (2020-06-11), XP055879485, Retrieved from the Internet <URL:https://ccforum.biomedcentral.com/track/pdf/10.1186/s13054-020-03020-3.pdf> [retrieved on 20231220], DOI: 10.1186/s13054-020-03020-3 *
PERLIN DAVID S ET AL: "Levels of the TNF-Related Cytokine LIGHT Increase in Hospitalized COVID-19 Patients with Cytokine Release Syndrome and ARDS", MSPHERE, vol. 5, no. 4, 12 August 2020 (2020-08-12), pages e00699 - 20, XP093114352, DOI: 10.1128/mSphere.00699-20 *
PERLIN DAVID S. ET AL: "Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndrome", THE JOURNAL OF CLINICAL INVESTIGATION : JCI, vol. 132, no. 3, 1 February 2022 (2022-02-01), US, XP093114353, ISSN: 1558-8238, DOI: 10.1172/JCI153173 *
RAGEL EMMA J ET AL: "Acute respiratory distress syndrome: potential of therapeutic interventions effective in treating progression from COVID-19 to treat progression from other illnesses-a systematic review", BMJ OPEN RESPIRATORY RESEARCH, vol. 10, no. 1, 1 September 2023 (2023-09-01), pages e001525, XP093114358, ISSN: 2052-4439, DOI: 10.1136/bmjresp-2022-001525 *

Also Published As

Publication number Publication date
JP2023520216A (en) 2023-05-16
US11708406B2 (en) 2023-07-25
WO2021202649A2 (en) 2021-10-07
CA3173873A1 (en) 2021-10-07
EP4126945A2 (en) 2023-02-08
WO2021202649A3 (en) 2021-11-11
US20210324066A1 (en) 2021-10-21
BR112022019112A2 (en) 2022-11-08
AU2021248833A1 (en) 2022-09-22
MX2022011811A (en) 2022-10-07
KR20220161387A (en) 2022-12-06
TW202204405A (en) 2022-02-01
US20240002492A1 (en) 2024-01-04
CN115768791A (en) 2023-03-07

Similar Documents

Publication Publication Date Title
AU2018317824A1 (en) Light based therapy devices and methods
EP3668594A4 (en) Light based therapy devices and methods
CA196783S (en) Light therapy device
EP3873596A4 (en) Light therapy treatment method and apparatus
IL280677A (en) Tissue treatment with sensitizer and light and/or sound
EP4138933A4 (en) Anti-infective light radiation methods and devices
GB202019767D0 (en) Compostitions and methods
EP4126945A4 (en) Methods and treatment involving excess free light
GB202213962D0 (en) Use and method
EP4135836A4 (en) Light treatment device
GB202205901D0 (en) Optical properties and methods for UV treatment
EP4082577A4 (en) Cancer treatment method and medicine
GB202103872D0 (en) Uses and methods
SG11202104905PA (en) Wearable phototherapy apparatus with anti-viral and other effects
GB202016058D0 (en) Therapeautic treatment
GB202003722D0 (en) Treatment
GB202002711D0 (en) Treatment
GB201908760D0 (en) Optical devices and methods
IL279033A (en) Light therapy method and device
EP3597607A4 (en) Ballast water treatment device and ballast water treatment method
IL297241A (en) Therapeutic lighting devices and methods
CA196784S (en) Light therapy device
EP4138997A4 (en) Vaginal light therapy devices and methods for using them
GB202110940D0 (en) Method and use
GB202011324D0 (en) Method and Use

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221024

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07K0016240000

Ipc: C07K0016280000

A4 Supplementary search report drawn up and despatched

Effective date: 20240129

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101ALI20240123BHEP

Ipc: A61P 31/14 20060101ALI20240123BHEP

Ipc: A61P 37/06 20060101ALI20240123BHEP

Ipc: A61P 29/00 20060101ALI20240123BHEP

Ipc: A61P 11/00 20060101ALI20240123BHEP

Ipc: A61P 1/00 20060101ALI20240123BHEP

Ipc: A61K 39/395 20060101ALI20240123BHEP

Ipc: C07K 16/28 20060101AFI20240123BHEP